Navigation Links
Halozyme Therapeutics Reports First Quarter 2011 Financial Results
Date:5/6/2011

SAN DIEGO, May 6, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, cancer, dermatology and drug delivery markets, today reported financial results for the first quarter 2011.

(Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

"The faster insulin absorption and shorter duration of action observed in our first ultrafast insulin pump study is exciting," stated Gregory I. Frost, Ph.D., Halozyme's president and CEO. "Patients with diabetes that use insulin pumps could see unique benefits from Halozyme's Ultrafast Insulin."

First Quarter 2011 and Recent Business Highlights

  • Halozyme presented preliminary results from its first Ultrafast Insulin study in type 1 diabetes patients who receive their treatment with an insulin pump demonstrating that Aspart-PH20 generates a faster-in and faster-out profile with accelerated insulin absorption and a shorter duration of action compared to aspart alone. Aspart-PH20 is a formulation of Halozyme's rHuPH20 (recombinant human hyaluronidase) enzyme with the active ingredient in NovoLog® that was administered as a continuous subcutaneous insulin infusion over 72 hours with an insulin pump. Halozyme presented these results at the American Association of Clinical Endocrinologists meeting in San Diego on April 14, 2011.  
  • American Diabetes Association (ADA) 71s
    '/>"/>

  • SOURCE Halozyme Therapeutics, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related biology technology :

    1. Halozymes Ultrafast Insulin Generates Faster-In and Faster-Out Profile for Type 1 Diabetes Patients Using Insulin Pumps
    2. Halozyme Announces Roche Doses First Patient in Phase 3 Clinical Trial With Subcutaneous MabThera® (rituximab)
    3. Halozyme Therapeutics Reports Third Quarter 2010 Financial Results
    4. Halozyme Receives $5.5 Million Payment From Baxter
    5. Halozyme Therapeutics Reports 2008 Third Quarter Financial Results
    6. Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients
    7. Halozyme Therapeutics Announces Conference Call on November 6 to Review Third Quarter Results
    8. Halozyme Therapeutics to Present at Upcoming Investor Conferences
    9. Halozyme Therapeutics to Host Research Day for Investors and Analysts
    10. Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development
    11. Halozyme Therapeutics to Present at Upcoming Investor Conferences
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/23/2015)... Biofertilizers stimulate microbial activities in soil. These microorganisms ... the activities in the soil or in the rhizosphere. ... stress on reducing environmental pollution and on reducing the ... segments the bio fertilizers market with analysis and forecasting ...
    (Date:1/22/2015)... today announces the firm brokered a long-term lease totaling 202,492 ... company, at Two Ledgemont Center in Lexington, Massachusetts ... and Brian Cohen , senior vice president, represented Shire ... Hayden Ave. Photo - http://photos.prnewswire.com/prnh/20150122/170765 ...
    (Date:1/22/2015)... Protocol Networks brings independent technology consulting to ... independent consultants, Protocol Networks has recently announced its expansion ... years, his company has attracted several clients in The ... well as others. With the success of these engagements, ...
    (Date:1/22/2015)... Controlled Substance Compliance Services (CSCS), a project managed ... legal requirements around using controlled substances in pharmaceutical research, ... their international operations expand and become increasingly complex, large ... a result of the first phase of the CSCS ...
    Breaking Biology Technology:Biofertilizers Market Expected to Reach $1,649.7 Million by 2019 - New Report By MarketsandMarkets 2Biofertilizers Market Expected to Reach $1,649.7 Million by 2019 - New Report By MarketsandMarkets 3Biofertilizers Market Expected to Reach $1,649.7 Million by 2019 - New Report By MarketsandMarkets 4Transwestern | RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Protocol Networks Brings Independent Technology Consulting to the Constitution State 2Global Compliance Service for Controlled Substances to Expand to China 2
    ... Dec. 7 CVF Technologies,Corporation,s (OTC Bulletin Board: CNVT) ... a customer in Beijing, China for a,Biofiltair odor control ... China to approximately $500,000 (Cdn) and is the third ... "We are pleased that our technology was accepted on ...
    ... 7 Tutogen Medical, Inc.,(Amex: TTG ), a ... (allograft) and animal (xenograft) tissue, will report,financial results for ... on Monday, December 10, 2007 at 4:30 p.m. ET., ... (888) 408-9532 or,(706) 679-5064 or by accessing the web ...
    ... Products for the Long-Term Care Channel, ... Inc., wholly owned subsidiary of Millennium Biotechnologies,Group, ... that the initial,$200,000.00 monthly shipment from Millennium ... under the previously announced $20,000,000,Five- year exclusive ...
    Cached Biology Technology:CVF Technologies Corporation's Holding - BIOREM Announces 3rd Order from China 2Tutogen Medical, Inc. to Report Fourth Quarter and Fiscal Year 2007 Financial Results 2Millennium Ships and Records the First $200,000 of Revenue Generated From the Five-Year $20,000,000 Exclusive Purchase Order 2Millennium Ships and Records the First $200,000 of Revenue Generated From the Five-Year $20,000,000 Exclusive Purchase Order 3
    (Date:12/19/2014)... Calif. , Dec. 18, 2014  23andMe, Inc., the leading ... that pinpoints fine-scale differences in genetic ancestry of individuals from ... Since immigrants first arrived more than four hundred years ago, ... a meeting place for peoples from different continents. This study ...
    (Date:12/17/2014)... , Dec. 15, 2014  HITLAB SM announced ... audit to confirm its adherence to current U.S. Food ... to conduct regulated smart device and smart phone application ... research quality. "HITLAB is determined to improve ...
    (Date:12/15/2014)... DUBLIN , Dec. 12, 2014 Research and Markets ... of the "Global Facial Recognition Market 2015-2019" ... http://photos.prnewswire.com/prnh/20130307/600769 Facial recognition is a technology ... measures the overall facial feature of a person such ...
    Breaking Biology News(10 mins):23andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
    ... Institute for Biological Studies discovered that cells co-opted the ... protect the integrity of chromosomes. This finding solves for ... puzzled scientists. , The natural ends of chromosomes look ... repair machinery is designed to fix. But mending chromosome ...
    ... very earliest genetic changes involved in the development of lung ... mouse that develops the disease in much the same way ... 1 issue of Cancer Research, open the door to the ... the very first signs of lung cancer, when the possibility ...
    ... pathogenic fungi as model systems for understanding fungal diseases, ... offers insight into how carbon dioxide (CO2) governs the ... different environments and invade the human body, and they ... utilize evolutionarily conserved enzymes to control the growth and ...
    Cached Biology News:Normal chromosome ends elicit a limited DNA damage response 2Building a better mouse model of lung cancer: FHIT counts 2Building a better mouse model of lung cancer: FHIT counts 3CO2 sensing proves critical for fungal pathogens to adapt to life in air and human hosts 2CO2 sensing proves critical for fungal pathogens to adapt to life in air and human hosts 3
    Anti-Mouse Macrophages (Metallophillic), Purified (Clone MOMA-1) (rat IgG2a)...
    Request Info...
    Human Osteocalcin (1-22) mature form. Also reacts with Osteocalcin (1-44) and Osteocalcin (1-49). No reactivity with Bone sialoprotein....
    TGF-beta 1,-2,-3 MAb (Clone 1D11)...
    Biology Products: